Cardiogenic shock

Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock

Thursday, October 14, 2021 - 12:30pm

Additionally, Windtree will discuss its development program for istaroxime in early cardiogenic shock, which is currently in a Phase 2 study with targeted completion in Q4 2021.

Key Points: 
  • Additionally, Windtree will discuss its development program for istaroxime in early cardiogenic shock, which is currently in a Phase 2 study with targeted completion in Q4 2021.
  • (UK) is Director of Heart Failure and of the Echocardiography Laboratory at the San Francisco Veterans Affairs Medical Center in San Francisco, California.
  • He also currently serves on the Acute Heart Failure Committee of the European Society of Cardiology Heart Failure Association and has served on the National Committee on Heart Failure and Transplantation of the American Heart Association.
  • Windtree Therapeutics, Inc.is advancing multiple late-stage interventions for acute cardiovascular and acute pulmonary disorders to treat patients in moments of crisis.

Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results from its Istaroxime ECS Study

Tuesday, October 12, 2021 - 12:30pm

After two positive istaroxime phase 2 acute heart failure studies provided the rationale, Windtree began clinical development of istaroxime in the second disease state of early cardiogenic shock.

Key Points: 
  • After two positive istaroxime phase 2 acute heart failure studies provided the rationale, Windtree began clinical development of istaroxime in the second disease state of early cardiogenic shock.
  • Using cardiogenic shock patient US hospital claims and worldwide prevalence data, Windtree estimates the worldwide total market value of cardiogenic shock to be $1.25 billion.
  • 99 out of 100 cardiologists responded that there was high need for pharmacologic (drug) innovation in SCAI class B cardiogenic shock patients.
  • The istaroxime Phase 2 study in early cardiogenic shock is an international, randomized, double blind, placebo- controlled study.

Legend Capital leads ForQaly Medical's Series B financing

Friday, October 8, 2021 - 7:13am

Recently, it completed its Series B fundraising led by Legend Capital, followed by CD Capital, SAIF Partners, Chengwei Chuangban and Co-win Ventures.

Key Points: 
  • Recently, it completed its Series B fundraising led by Legend Capital, followed by CD Capital, SAIF Partners, Chengwei Chuangban and Co-win Ventures.
  • Existing investors Lilly Asia Ventures and Kaitai Capital also participated in the funding round.
  • Joe Zhou, the Managing Director of Legend Capital, said: "VAD, especially the interventional one, has a huge market prospect in China.
  • We are glad to partner with ForQaly Medical and will establish a long-term cooperation with the company.

ZOLL’s TherOx SuperSaturated Oxygen Therapy to Be Highlighted at SCAI Shock Virtual Conference

Tuesday, October 5, 2021 - 2:00pm

ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its TherOx SuperSaturated Oxygen (SSO2) Therapy will be the focus of a panel discussion at the upcoming Society for Cardiovascular Angiography & Interventions (SCAI) Shock virtual conference October 7-8.

Key Points: 
  • ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its TherOx SuperSaturated Oxygen (SSO2) Therapy will be the focus of a panel discussion at the upcoming Society for Cardiovascular Angiography & Interventions (SCAI) Shock virtual conference October 7-8.
  • SuperSaturated Oxygen (SSO2) Therapy is the first and only FDA-approved treatment to significantly reduce myocardial damage in heart attack patients after percutaneous coronary intervention.
  • SSO2 Therapy was developed by Irvine, California-based TherOx, Inc., now part of ZOLL.
  • TherOx and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.

Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

Thursday, September 16, 2021 - 12:30pm

WARRINGTON, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit.

Key Points: 
  • WARRINGTON, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit.
  • The Companys presentation will take place on Wednesday, September 22, 2021 at 9:55 am ET.
  • A live webcast and replay of the presentation will be available on the Investor Events page ( https://ir.windtreetx.com/events ) of the companys website ( www.windtreetx.com ).
  • Windtree Therapeutics, Inc.is advancing multiple late-stage interventions for acute cardiovascular and acute pulmonary disorders to treat patients in moments of crisis.

CARDIOGENICS HOLDINGS INC. ANNOUNCES LICENSE AGREEMENT AND DIVIDEND DISTRIBUTION

Friday, September 3, 2021 - 10:20pm

Caledon, Ontario, Sept. 03, 2021 (GLOBE NEWSWIRE) -- CardioGenics Holdings Inc. (OTC PINK: CGNH) (theCompany)announced todaythat its subsidiary, CardioGenics Inc. (CardioGenics), has entered into a license agreement with Covidgenics Corp., a private company located in Ontario, which grants to Covidgenics an exclusive 10-year global license of the Companys proprietary technology for its QL Care Analyzer and paramagnetic beads.

Key Points: 
  • Caledon, Ontario, Sept. 03, 2021 (GLOBE NEWSWIRE) -- CardioGenics Holdings Inc. (OTC PINK: CGNH) (theCompany)announced todaythat its subsidiary, CardioGenics Inc. (CardioGenics), has entered into a license agreement with Covidgenics Corp., a private company located in Ontario, which grants to Covidgenics an exclusive 10-year global license of the Companys proprietary technology for its QL Care Analyzer and paramagnetic beads.
  • In order to provide the Companys shareholders an opportunity to participate directly in any increased value that may develop from Covidgenics further development efforts, the Company intends to issue to its shareholders, as a dividend, the Covidgenicsshares received by CardioGenics under the license agreement, subject to compliance with all applicable laws.
  • CardioGenics Holdings intends to deliver the Covidgenics shares to its shareholders on a pro rata basis according to their holdings as of a record date of September 13, 2021.
  • The shares distributed to CardioGenics Holdings shareholders will be held, in the shareholder name, at Covidgenics.

FDA Grants Breakthrough Device Designation to Impella ECP, the World’s Smallest Heart Pump

Wednesday, August 18, 2021 - 1:02pm

The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump.

Key Points: 
  • The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump.
  • The FDA granted breakthrough device designation in part based on positive clinical data from the first 21 Impella ECP patients treated as part of an FDA regulated early feasibility study.
  • In granting the designation, the FDA determined Impella ECP meets the FDAs stringent requirements for a breakthrough device .
  • The Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella LD, and Impella 5.5 with SmartAssist are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

Amring Pharmaceuticals Inc. Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP

Thursday, August 5, 2021 - 9:44pm

Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2 mg/mL) available as 1 mL or 5 mL Single-Dose Vials, (AP rated generic equivalent of Isuprel), and has immediately begun commercialization activity.

Key Points: 
  • Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2 mg/mL) available as 1 mL or 5 mL Single-Dose Vials, (AP rated generic equivalent of Isuprel), and has immediately begun commercialization activity.
  • "We are pleased to add Isoproterenol Hydrochloride Injection USP to our generics portfolio, this product brings long term value to patients and customers in our target markets, stated Daniel Carbery, President and CEO of Amring.
  • We look forward to realizing the benefits of this, and other product launches and future business development activities in 2021.
  • Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market.

Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates

Thursday, August 5, 2021 - 9:01pm

WARRINGTON, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2021 and provided key business updates.

Key Points: 
  • WARRINGTON, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2021 and provided key business updates.
  • The Company currently has 12 participating trial sites, with data anticipated in the fourth quarter of 2021.
  • Research and development expenses were $4.2 million for the second quarter of 2021, compared to $4.5 million for the second quarter of 2020.
  • General and administrative expenses for the second quarter of 2021 were $3.4 million, compared to $3.5 million for the second quarter of 2020.

ZOLL Medical Receives FDA IDE Approval for Initiation of ISO Shock (Incorporating Supersaturated Oxygen in Shock) Feasibility Study

Thursday, May 13, 2021 - 1:30pm

The ISO SHOCK study will assess the safety and feasibility of SSO2 Therapy in patients with this complex and highly fatal condition and potentially lay the groundwork for future trials to benefit high-risk heart attack patients.\nThis press release features multimedia.

Key Points: 
  • The ISO SHOCK study will assess the safety and feasibility of SSO2 Therapy in patients with this complex and highly fatal condition and potentially lay the groundwork for future trials to benefit high-risk heart attack patients.\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210513005131/en/\nZOLL\xe2\x80\x99s TherOx System delivers SuperSaturated Oxygen Therapy immediately post-PCI to reduce infarct size.
  • Cardiogenic shock represents the highest risk category of STEMI with the greatest myocardial damage from ischemia.
  • TherOx and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.